Drug approvals in the United States between 2010-2019 were aligned with the US, but not global, burden of disease and the increasing number of expedited drug approvals could… read more.
Researchers report that, among pregnant women with a short cervix at around 20 weeks, treatment with the hormone progesterone achieves a better result at reducing the risk of… read more.
Sandoz, announced that the FDA approved Wyost (denosuab-bbdz) and Jubbonti (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines Keren Haruvi,… read more.
SpringWorks Therapeutics, Inc. announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of… read more.
Alvotech announced that it has reached settlement agreements with Johnson & Johnson in Japan, Canada and in the European Economic Area (EEA) for AVT 04, a biosimilar to… read more.
Drug development is currently an extremely long, expensive and inefficient process. Findings generated in a lab are often very hard to replicate once translated into animal models or… read more.
Any drug that is taken orally must pass through the lining of the digestive tract. Transporter proteins found on cells that line the GI tract help with this… read more.
Phosphodiesterase type 5 inhibitors (PDE5Is) used to treat erectile dysfunction might also reduce the risk of Alzheimer’s disease onset, researchers reported on Feb. 7, 2024 in Neurology. “Although… read more.
In patients with major depression disorder it is, thanks to use of artificial intelligence, now possible to predict within a week whether an antidepressant will work. With the… read more.
Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for… read more.
Sandoz announces the launch of Tyruko (natalizumab) in Germany from February Developed by Polpharma Biologics, Tyruko is the first and only biosimilar to treat RRMS.(r/r Multiple Sclerosis). Tyruko… read more.
To treat depression in heart failure, patients can receive with similar efficacy either behavioral activation psychotherapy or antidepressant drug therapy, researchers report. The findings appeared on Jan.17, 2024… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
